Monoclonal antibodies against muscle actin isoforms: epitope identification and analysis of isoform expression by immunoblot and immunostaining in normal and regenerating skeletal muscle [version 2; peer review: 3 approved]

Christine Chaponnier, Giulio Gabbiani
Department of Pathology-Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland

Abstract
Higher vertebrates (mammals and birds) express six different highly conserved actin isoforms that can be classified in three subgroups: 1) sarcomeric actins, α-skeletal (α-SKA) and α-cardiac (α-CAA), 2) smooth muscle actins (SMAs), α-SMA and γ-SMA, and 3) cytoplasmic actins (CYAs), β-CYA and γ-CYA. The variations among isoactins, in each subgroup, are due to 3-4 amino acid differences located in their acetylated N-decapeptide sequence. The first monoclonal antibody (mAb) against an actin isoform (α-SMA) was produced and characterized in our laboratory in 1986 (Skalli et al., 1986). We have further obtained mAbs against the 5 other isoforms. In this report, we focus on the mAbs anti-α-SKA and anti-α-CAA obtained after immunization of mice with the respective acetylated N-terminal decapetides using the Repetitive Immunizations at Multiple Sites Strategy (RIIMMS). In addition to the identification of their epitope by immunoblotting, we describe the expression of the 2 sarcomeric actins in mature skeletal muscle and during muscle repair after micro-lesions. In particular, we analyze the expression of α-CAA, α-SKA and α-SMA by co-immunostaining in a time course frame during the muscle repair process. Our results indicate that a restricted myocyte population expresses α-CAA and suggest a high capacity of self-regeneration in muscle cells. These antibodies may represent a helpful tool for the follow-up of muscle regeneration and pathological changes.

Keywords
Actin isoforms, monoclonal antibodies, epitope, muscle repair

This article is included in the Antibody Validations gateway.
Corresponding authors: Christine Chaponnier (christine.chaponnier@unige.ch), Giulio Gabbiani (giulio.gabbiani@unige.ch)

Competing interests: The authors sell the anti-actin isoform antibodies to companies through Unitec, University of Geneva, unitec@unige.ch

Grant information: This work was supported by the Swiss National Science Foundation (grant number 310030_125320) to C.C.

Copyright: © 2016 Chaponnier C and Gabbiani G. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

How to cite this article: Chaponnier C and Gabbiani G. Monoclonal antibodies against muscle actin isoforms: epitope identification and analysis of isoform expression by immunoblot and immunostaining in normal and regenerating skeletal muscle [version 2; peer review: 3 approved] F1000Research 2016, 5:416 (https://doi.org/10.12688/f1000research.8154.2)

Introduction

Expression of actin isoforms in skeletal muscle at the mRNA and protein levels have been described since the 1980s using tissue extracts (Gunning et al., 1983; Hayward & Schwartz, 1986; Hayward et al., 1988; Minty et al., 1982; Orbdal, 1986; Paterson & Eldridge, 1984; Sassoon et al., 1988; Vandekerckhove et al., 1986). These studies have indicated that sarcomeric actins (α-CAA and α-SKA) are expressed in fetal and regenerating skeletal muscle, whereas α-SKA becomes the predominant actin isoform in mature skeletal muscle. Noteworthy, during fetal life, another actin isoform, α-SMA, is highly expressed and precedes the sarcomeric isoforms (Bochaton-Piallat et al., 1992; Hayward & Schwartz, 1986; McHugh et al., 1991; Woodcock-Mitchell et al., 1988).

Nevertheless, very little is known concerning the precise localization of these isoforms due to the lack of specific α-SKA and α-CAA antibodies. The first mAb against α-CAA has allowed the identification, by immunohistochemistry, of a α-CAA transient expression in human skeletal muscle satellite cells during skeletal regeneration induced by muscle injury, while normal skeletal muscle was negative (Franke et al., 1996). Ten years later, the same group, in a more extensive study, has further analyzed the expression and localization of α-CAA in normal, regenerating, diseased and neoplastic human muscle tissues (Moll et al., 2006). In human fetal skeletal muscle, a uniform strong α-CAA staining was observed while in normal adult skeletal muscle, α-CAA was identified only in few thin fibers. α-CAA staining of thin fibers became stronger in human regenerating skeletal muscle after traumatic injury, as well as in Duchenne muscular dystrophy (DMD). Whether the persistence of α-CAA in DMD myotubes is due to a lack of differentiation or to a regenerative process deserves further examination. Interestingly, resting satellite cells in healthy adult muscle lack this isoform, whereas, when satellite cells are activated during the regeneration process, α-CAA is up-regulated. Unfortunately, in these two studies, a comparative α-SKA staining was not performed.

In a more recent study, the switch of α-CAA to α-SKA during the differentiation of skeletal muscle from mouse embryonic stem cells has been examined (Mizuno et al., 2009). In this in vitro system, α-CAA appeared first in myoblasts, with no staining for α-SKA. During cell fusion, α-SKA appeared. When myotubes began to form sarcomeres, α-SKA expression increased while α-CAA began to decrease. Finally, mature skeletal muscle fibers were mainly composed of α-SKA. Although, this in vitro system seems to recapitulate the in vivo skeletal muscle differentiation at the level of sarcomeric actins switching, the in vivo origin of progenitor cells during in vivo muscle differentiation/repair remains elusive.

The sequential expression of the two striated actins during: i) heart development (high expression of α-SKA at birth, predominant expression of α-CAA in differentiated cardiac muscle at adult life) and ii) skeletal muscle development (high expression of α-CAA at birth, predominant of α-SKA in differentiated skeletal muscle at adult life) has been known from mRNA studies for decades, but little is known about the distribution and/or the localization of the two α-sarcomeric muscle actins, because of the lack of double immunostainings availability. Nevertheless, our laboratory, in collaboration with others, has studied α-SKA expression and distribution, in particular in developing and pathological hearts, using affinity polyclonal antibodies (Clément et al., 1999), again without double immunostaining.

As mentioned above, α-CAA distribution has been studied during muscle development and repair (Moll et al., 2006), but a comparative study with α-SKA was still missing. Our mAbs were raised using the acetylated N-terminus decapeptide of each isoform (see Table 1). The two different mAb subtypes (anti-α-SKA, IgG2b and anti-α-CAA, IgG1), allowed a clear analysis of the expression and distribution of the two actin isoforms in mature skeletal muscle and during regeneration after micro-lesions by means of highly specific anti-mouse subtype secondary antibodies.

Materials and methods

Reagents details

Details of all reagents with reference to the immunoblot and immunostaining procedure can be found in Table 2 and Table 3. Crucial are the conditions of fixation and permeabilization for relevant immunostaining. With cells in culture as well as with tissues, we have tested a large number of conditions such as MeOH, EtOH, PFA-TX100. By far, the use of PFA, followed by MeOH, as described in Table 3 and previously defined (Dugina et al., 2009), allowed the best detection of every actin isoform, likely because of availability of the actin molecule N-terminus.

Animals

All animal experiments (production of antibody in mice, rat wounds, tissue samplings) were approved by and performed in accordance with the cantonal and federal veterinary authorities.

Tissue details

Tibialis muscle specimens from female Wistar rats older than 10 weeks were rapidly embedded in OCT compound (Tissue-Tek), snap-frozen in a beaker containing precooled liquid isopentane, immersed in liquid nitrogen, and stored at -80°C. For muscle repair studies, rat tibial muscles were injured with a liquid nitrogen cooled needle, using a well-set simple rat model (Rocheteau et al., 2012). Muscles were taken, OCT embedded and frozen at different days after injury.
Table 1. List of monoclonal antibodies against the 6-actin isoforms raised in our laboratory. The epitope recognized by each antibody is enlightened in bold.

<table>
<thead>
<tr>
<th>Actin isoform</th>
<th>Immunogen</th>
<th>MAb name</th>
<th>Clone</th>
<th>Subtype</th>
<th>Original Reference</th>
<th>Distributors</th>
<th>Catalog Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-SMA</td>
<td>AcEEED</td>
<td>STALVC</td>
<td>Anti-α-SMA</td>
<td>1A4</td>
<td>IgG2a</td>
<td>Skalli et al., 1986</td>
<td>Abcam, AbD Serotec, Cell Marque Corporation, Dako, eBioscience, EMD Millipore, Genemed Biotechnologies, Nordic-MUbio, R&amp;D Systems, Santa Cruz Biotechnology, Sigma-Aldrich, Spring Bioscience, Zeta Corporation</td>
</tr>
<tr>
<td>γ-SMA</td>
<td>AcEEETTA</td>
<td>LVC</td>
<td>Anti-γ-SMA</td>
<td>20D2</td>
<td>IgG1</td>
<td>Arnoldi et al., 2013</td>
<td>NA</td>
</tr>
<tr>
<td>β-CYA</td>
<td>AcDDDD</td>
<td>AALVC</td>
<td>Anti-β-CYA</td>
<td>4C2</td>
<td>IgG1</td>
<td>Dugina et al., 2009</td>
<td>AbD Serotec, EMD Millipore, Nordic-MUbio</td>
</tr>
<tr>
<td>γ-CYA</td>
<td>AcEEBAAL</td>
<td>VC</td>
<td>Anti-γ-CYA</td>
<td>2A3</td>
<td>IgG2b</td>
<td>Dugina et al., 2009</td>
<td>AbD Serotec, EMD Millipore, Nordic-MUbio</td>
</tr>
<tr>
<td>α-SKA and α-CAA Sarcomeric actins</td>
<td>Rabbit skeletal actin</td>
<td>Anti-α-SR1</td>
<td>5C5</td>
<td>IgM</td>
<td>Skalli et al., 1988</td>
<td>Dako, Santa Cruz Biotechnology, Sigma-Aldrich, Spring Bioscience</td>
<td>M0874 sc-58670 A2172 E16654</td>
</tr>
<tr>
<td>α-SKA</td>
<td>AcDEDDETT</td>
<td>LVC</td>
<td>Anti-α-SKA</td>
<td>3B3</td>
<td>IgG1</td>
<td>Driesen et al., 2009</td>
<td>Nordic-MUbio</td>
</tr>
<tr>
<td>α-SKA</td>
<td>AcDEDDETT</td>
<td>LVC</td>
<td>Anti-α-SKA</td>
<td>10D2</td>
<td>IgG2a</td>
<td>Driesen et al., 2009</td>
<td>NA</td>
</tr>
<tr>
<td>α-CAA</td>
<td>AcDDDEET</td>
<td>TALVC</td>
<td>Anti-α-CAA</td>
<td>22D3</td>
<td>IgG1</td>
<td>Driesen et al., 2009</td>
<td>EMD Millipore, Nordic-MUbio</td>
</tr>
</tbody>
</table>
Table 2. Western blot protocol for the identification of the epitopes recognized by anti-α-SKA (clone 10D2) and anti-α-CAA (clone 22D3).

<table>
<thead>
<tr>
<th>Protocol steps</th>
<th>Reagent</th>
<th>Concentration/dilution</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Migration of Purified α-SKA and α-CAA on SDS-PAGE</td>
<td>1μg/lane</td>
<td>overnight</td>
<td></td>
</tr>
<tr>
<td>• Transfer on Nitrocellulose membranes.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Membranes cut in strips for Ab-peptides incubation.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preincubation of antibodies with peptides</td>
<td>MAb:</td>
<td>1:5000</td>
<td>1 h</td>
</tr>
<tr>
<td></td>
<td>• anti-α-SKA (10D2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• anti-α-CAA (22D3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>For details, see Table 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blocking Peptides (see Figure 1)</td>
<td>100 μg/ml</td>
<td></td>
</tr>
<tr>
<td>Membranes pretreatment</td>
<td>5% dried skimmed milk in TBS</td>
<td>5%</td>
<td>1 h</td>
</tr>
<tr>
<td>Membranes Incubation with antibody-peptides</td>
<td>In 0.1% TX-100/TBS</td>
<td>2 h</td>
<td></td>
</tr>
<tr>
<td>Membranes Incubation with 2nd antibody</td>
<td>Goat Anti-Mouse IgG (H+L) HRP Conjugate</td>
<td>1:10’000</td>
<td>1 h</td>
</tr>
<tr>
<td></td>
<td>(BioRad) #1706516</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>In 0.1% TX-100/TBS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HRP activity development</td>
<td>ECL protocol according to (RPN 2109; GE Healthcare),</td>
<td>5–60 sec</td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Details of immunofluorescence staining protocol.

<table>
<thead>
<tr>
<th>Protocol steps</th>
<th>Reagent</th>
<th>Concentration/dilution</th>
<th>Time</th>
<th>Catalogue Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Cryopreserved Rat muscles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Cryostat sections (3μm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixation</td>
<td>• Paraformaldehyde</td>
<td>1%</td>
<td>30 min at RT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Methanol</td>
<td>100%</td>
<td>5 min at –20°C</td>
<td></td>
</tr>
<tr>
<td>Staining</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Primary Abs: MAb:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• anti-α-SKA (10D2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• anti-α-CAA (22D3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• anti-α-SMA (1A4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>For details, see Table 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• anti-vimentin (clone V9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunogen: Purified vimentin from porcine eye lens</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specificity: the antibody cross-reacts with</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vimentin in man, cow, dog, hamster, horse, rhesus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and African green monkey, rabbit, rat and rat</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>kangaroo. No cross-reaction with mouse vimentin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>could be demonstrated, and results on chicken</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>specimens are contradictory.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rabbit polyclonal Ab:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• anti-α-CAA (Clément et al., 2003)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:100</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Secondary Abs (Jackson Immunoresearch):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• AffiniPure Goat Anti-Mouse IgG1, Alexa 488</td>
<td>1:200</td>
<td>1 h</td>
<td>115-545-205</td>
</tr>
<tr>
<td></td>
<td>• AffiniPure Goat Anti-Mouse IgG1, Alexa 594</td>
<td>1:200</td>
<td></td>
<td>115-585-205</td>
</tr>
<tr>
<td></td>
<td>• AffiniPure Goat Anti-Mouse IgG2a, Alexa 488</td>
<td>1:200</td>
<td></td>
<td>115-545-206</td>
</tr>
<tr>
<td></td>
<td>• AffiniPure Goat Anti-Mouse IgG2a, Alexa 594</td>
<td>1:200</td>
<td></td>
<td>115-585-206</td>
</tr>
<tr>
<td></td>
<td>• AffiniPure Goat Anti-Rabbit-Alexa 594</td>
<td>1:100</td>
<td></td>
<td>111-585-144</td>
</tr>
</tbody>
</table>
Antibody production and details

MAbs against α-SKA and α-CAA were prepared following the Repetitive Immunizations Multiple Sites (RIMMS) strategy (Kilpatrick et al., 1997). This strategy uses lymphocytes from regional draining lymph nodes and an immunization schedule significantly shorter than conventional techniques: two weeks instead of several months. Along with the use of less antigen, this approach allows to obtain hybridomas in a month.

Mice were immunized with the acetylated N-terminal decapeptide of α-SKA (Ac-DEDETTALVC-COOH) or α-CAA (Ac-DDEET-TALVC-COOH) conjugated with keyhole limpet haemocyanin through the cysteine peptide C-terminus (KLH, Injekt Maleimide Activated carrier proteins, Pierce) according to the instructions of the manufacturer. Briefly, over a period of 10 days, 5 injections of 5 μg of protein (α-SKA or α-CAA peptide x KLH) emulsified in complete Freund’s adjuvant (first injection) or with incomplete Freund’s adjuvant (for the remaining injections) and RIBI adjuvants (Sigma-Aldrich) were given at six subcutaneous sites proximal to draining peripheral lymph nodes (PLNs) in three anesthetized six-week-old female BALB/c mice (200μl/mice). Two days after the final boosts, animals were sacrificed. PLNs were harvested from popliteal, superficial inguinal, axillary, and brachial lymph nodes and dissociated. Up to 1 × 10⁶ lymphocytes per 3 mice, were used for fusions with 2.5 × 10⁶ with NSO myeloma cells using 50% polyethylene glycol (PEG 1500, Sigma-Aldrich). Fused cells were plated in 24-well tissue culture plates (4000 cells/well). Hybridomas were grown in DMEM+ pyruvate, 5% FCS, 10% NCTC 109 (Sigma-Aldrich), 1× MEM Non-Essential Amino Acids (Gibco), 1% Hybridoma Fusion and Cloning Supplement (HFCS, Roche), penicillin/streptomycin, and 1× selective media hypoxanthine/aminopterin/thymidine (HAT). Supernatants were harvested after 2 weeks and screened for antibody specificity by ELISA and immunofluorescence staining (see below). Hybridomas from wells of interest were distributed into 96-well plates (1-2-5-10 cells/well) for the first limited dilution using 1× hypoxanthine and thymidine (HT) in place of HAT. After about 10 days of culture, wells with single clones were identified by microscope and their supernatants were harvested for screening. Positive clones were re-plated using another limited dilution for a further 10 days in DMEM containing 10% FCS and antibiotics. Clones secreting the specific mAb were expanded and frozen. Hybridomas were cultivated at post confluence in the same medium for mAb production. Sodium azide (0.1%) was added to the supernatants for storage. See Table 2 and Table 3 for working dilution.

Supernatants of hybridoma cells secreting anti-α-SKA or anti-α-CAA were screened by: i) triple ELISA, using 96 well plates coated with α-SMA, α-SKA and α-CAA BSA-conjugated peptides, using Maleimide Activated BSA (Pierce) according to the instructions of the manufacturer; ii) Western blotting using platelets, heart, aorta, skeletal muscle, gizzard extracts (Driessen et al., 2009); iii) immunofluorescence using rat lip, skeletal and heart sections. Selected hybridomas were cloned twice by limited dilution, as described above, and the final mAb characterization was performed by immunoblotting after transfer of one-dimensional gels containing tissue and cell extracts and finally by blocking assays (Chaponnier et al., 1995) using the N-terminal peptides of α-SKA and α-CAA.

Electrophoresis and immunoblot analysis

Purified α-SKA (Spudich & Watt, 1971) and α-CAA (Zot & Potter, 1981) were run on 10% SDS-PAGE (Laemmli, 1970) and electroblotted to nitrocellulose according to Towbin et al. (Towbin et al., 1979). After preincubation with the respective different length peptides (listed in Figure 1), the antibodies, diluted in Tris-buffered saline (TBS) solution containing 3% BSA and 0.1% Triton X-100, were incubated on membranes strips for two hours at room temperature. After 3 washes with TBS, a second incubation was performed with peroxidase-conjugated affinity purified goat anti-rabbit IgG (Biorad) at a dilution of 1:10,000 in TBS containing 0.1% BSA and 0.1% Triton X-100. Peroxidase activity was developed using the ECL Western blotting
system (GE Healthcare), exposed to AX Konica Minolta films for 5–60 sec, and processed with Curix-60 developing machine (Agfa). Blots were scanned and quantified using densitometric analysis ImageJ v1.49 software (NIH, http://rsb.info.nih.gov/ij/).

Immunofluorescence microscopy
Cryopreserved tissues were sliced (3 μm) with a cryostat microtome (Microm). Sections were positioned on glass slides, fixed with 1% PFA for 30 min at room temperature, followed by three washes with PBS and a 5 min treatment with methanol at -20°C. After three 5 min washes with PBS at RT, tissue sections on glass slides were incubated with primary (2h) and secondary antibodies (1h) at appropriate dilutions (see Table 3). Normal rat serum (1:50) was used to block non-specific sites, and DAPI for nuclear staining. After washing in PBS, sections on slides were mounted in polyvinyl alcohol (PVA: 50 mM Tris-phosphate pH 9.0, 0.1% chlorobutanol, 20% polyvinyl alcohol, 0.5‰ phenol red, 20% glycerol) (Lenette, 1978). Images were acquired using a Zeiss Axiohot microscope (Carl Zeiss), equipped with plan apochromatic 10x, 20x, or 40x objectives and a high sensibility color camera (Axiocam, Zeiss).

After a careful selection of highly specific secondary antibodies against mouse subtypes, testing a large panel of these antibodies, we selected those commercialized by Jackson Immunoresearch and Southern Biotechnology.

Results

Identification of the epitopes recognized by the actin isoform antibodies
Acetylated N-terminal peptide of different length (4–10 amino acids) and non-acetylated N-terminal decapeptide of α-SKA and α-CAA were tested for their blocking ability of the respective mAb (Figure 1). We identified the epitope of α-SKA (AcDEDETTA) and of α-CAA (AcDDEET). The epitope of the other actin isoforms were previously identified and are listed in Table 1 (in bold letters). Noteworthy, the acetyl group is a critical element of the epitope of each isoform.

Comparison of distribution of α-SKA and α-CAA, in mature skeletal muscle
The normal myonuclear turnover in rodents is estimated at 1–2% per week (Schmalbruch & Lewis, 2000). As a first investigation, we have compared the distribution of α-CAA with α-SKA, α-SMA and vimentin on cryostat sections of adult rat tibialis muscle. Although a minority of myocytes expressed α-CAA, we have observed two types of α-CAA positive cells in skeletal fibers: one was mainly located in interstitial connective tissue (Figure 2A, a–c, d–f) and the other was localized in the muscle mass (Figure 2A, g–i, arrowhead). The first type corresponded most likely the “muscle spindles”, described by Moll et al. (Moll et al., 2006), as “modified muscle fibers of neuromuscular spindles, believed to act as sensors of muscle tension”. The “spindle” cells expressed exclusively α-CAA, whereas the “classical muscle fibers”, in addition to a high expression of α-CAA, displayed α-SKA at various levels (Figure 2A, g–i, j–l), probably according to the state of differentiation during self-regeneration of myocytes.

It is well known that during skeletal muscle development, α-SMA is the first muscle actin to be expressed in myocytes during fetal life. Therefore, we also investigated the expression of α-SMA during muscle self-regeneration. We observed that a few regenerating α-CAA positive fibers displayed α-SMA (Figure 2B, d–f).

As vimentin is expressed in the capsule of muscle spindle cells (Cizková et al., 2009), we investigated further whether the α-CAA positive fibers located in interstitial spaces could be identified as component of muscle spindles. After co-staining of muscle sections for α-CAA and vimentin, we confirmed that a capsule containing vimentin-positive cells surrounded isolated α-CAA positive spindle fibers (Figure 2C, a–c). Noteworthy, regenerating fibers displayed contacts with vimentin positive cells (Figure 2C, d–f).

Distribution of α-SMA, α-SKA and α-CAA, in mature skeletal muscle during the repair process
The use of specific mAbs against actin isoforms allows the tracking and follow-up of myocytes regeneration during the muscle repair process. In particular, complete and fast repair can be observed after muscle micro-lesions obtained after light injury induced by nitrogen-cooled needle application. At early stage (4 day post-injury), an important population of α-CAA positive myofibers was observed (Figure 3A) at injury sites. These cells, being α-SKA negative or marginally positive, are probably in an early stage of differentiation. Few of them co-expressed α-SMA (Figure 3C, a–c, arrowhead). Only rarely, α-SMA positive myofibroblasts, the hallmark of fibrotic process (Tomasek et al., 2002) were detected (Figure 3C, a–c, arrow). At 5d post-injury, fibers started to express more importantly α-SKA in addition to α-CAA in the regenerating location (Figure 3B, a–f). In our model, muscle regeneration was very rapid, as expression of α-SMA was not any longer detectable 5d after injury (Figure 3C, d–f). At 9d post-injury, co-expression of α-SKA and α-CAA became rare (Figure 3B, g–i). These results suggest that skeletal
Figure 2. Rat adult skeletal muscle co-stained with isoform specific antibodies. A) Co-staining with anti-α-SKA (red) and anti-α-CAA (green) allows the detection of isolated thin α-CAA positive fibers in interstitial connective tissue (transversal sections, a–c: longitudinal section, d–f) and of regenerating muscle fibers expressing both isoforms (longitudinal section, g–l, arrowhead), or only α-CAA (arrow). Merged images are shown on right column. Bars = 50 μm. B) Co-staining with anti-α-CAA (green) and anti-α-SMA (red) shows that α-CAA positive spindle cells are in close connection with α-SMA positive vessel (a–c), that early muscle fiber self-regeneration is characterized by co-expression of both isoform (d–f, arrowhead), although more advanced regenerated fibers are only α-CAA positive (g–l). Merged images are shown on right column. Bar = 50 μm. C) Co-staining with anti-α-CAA (red) and anti-vimentin (green) allows the detection of α-CAA positive muscle spindle cells surrounded by a capsule containing vimentin positive cells (transversal section, a–c) and of regenerating α-CAA positive fibers in contact with vimentin positive cells (longitudinal section, d–f). Merged images are shown on right column. Bar = 50 μm.
Figure 3. Regenerating rat adult skeletal muscle co-stained with isoform specific antibodies. A) At 4d post-injury, co-staining with anti-α-SKA (red) and anti-α-CAA (green) shows the presence of α-CAA positive fibers in the injured muscle area (a–i). At this stage of regeneration, only a few fibers co-express both isoforms (d–i), with a low α-SKA level (g–i). Merged images are shown on right column. Bars = 50 μm. B) At 5d–9d post-injury, co-staining with anti-α-SKA (red) and anti-α-CAA (green) shows that after 5d, most fibers co-express both isoforms (a–f), whereas at 9d (g–i), α-SKA positive fibers become predominant. Merged images are shown on right column. Bars = 50 μm. C) At 4d–5d post-injury, co-staining with anti-α-SMA (red) and anti-α-CAA (green) shows that during the healing process, only a few fibers co-express both isoforms after 4d (a–c, arrowhead), whereas after 5d, only α-CAA positive fibers are detected (d–f). After 4d, myofibroblasts might participate to the repair process and are detected by using the anti-α- SMA mAb (a–c, arrow). Merged images are shown on right column. Bars = 50 μm.

muscle has a high capacity of regeneration after micro-injury and that actin isoform specific mAbs represent an important tool for muscle regeneration tracking.

Conclusion
In conclusion, α-CAA, in conjunction with the expression of α-SMA and α-SKA, appears to represent a valuable marker for the identification of myofibers regeneration in skeletal muscle and for the analysis of the degree of fiber differentiation. For this purpose, it is important to use well-characterized and specific antibodies. Furthermore, high quality anti-mouse subtype secondary antibodies allow double immunostaining necessary for this type of investigation.

Data availability

Author contributions
C.C. designed and performed research. C.C. and G.G. wrote the paper.

Competing interests
The authors sell the anti-actin isoform antibodies to companies through Unitec, University of Geneva, unitec@unige.ch

Grant information
This work was supported by the Swiss National Science Foundation (grant number 310030_125320) to C.C.

Acknowledgments
We thank Anita Hiltbrunner and Aman Ahmed Mohamed, for their high quality technical assistance, Dr. Marie-Luce Bochaton-Piallat for advice and help with Photoshop and Dr. Stéphane König, Department of Basic Neurosciences, for advice and discussion about the muscle micro-lesion model.
Supplemental Figures

**Supplemental Figure 1.** Immunodetection of α-CAA and α-SKA in total tissue extracts by Western blots. Coomassie Blue (CB) staining of bovine aorta (A), rat heart (B), rat skeletal muscle (C), human platelets (D), and chicken gizzard (E) total extracts. Immunodetection of total actin, α-CAA and α-SKA with specific mAbs in total extracts of the same tissues.

**Supplemental Figure 2.** Enlargement of Figure 2Af (a) and Figure 3Ai (b), showing that, either in normal adult muscle (a), or at 4d post-injury during the healing process (b), regenerating αCAA (green) positive myofibers with centrally located nuclei (blue) are detectable. Differentiated muscles express αSKA (red) with peripheral located nuclei (blue) in both situations.
References


Open Peer Review

Current Peer Review Status: ✓ ✓ ✓

Version 2

Reviewer Report 02 June 2016

https://doi.org/10.5256/f1000research.9468.r14123

© 2016 Hashimoto N. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Naohiro Hashimoto
Department of Regenerative Medicine, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, Ōbu, Japan

I understand the purpose of this report is the validation of the actin isoforms antibodies. Muscle biologists would like to hear answers for questions derived from this study.

For example:

1. What is a role of myofibroblasts appear in regenerating muscles and disease muscles?
2. Does each actin isoform play a distinct role during muscle regeneration?

Particularly, a role of aCAA in newly formed myofibers is interesting.

I expect the panel of antibodies against actin isoforms will help future studies to reveal distinct role(s) of actin isoforms in muscle regeneration.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 12 April 2016

https://doi.org/10.5256/f1000research.8771.r13217

© 2016 Ono S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Drs. Chaponnier and Gabbiani report production and validation of monoclonal antibodies that specifically recognize alpha-skeletal muscle actin (αSKA) or alpha-cardiac alpha actin (αCAA), which are different only in a few amino acids at the N-terminus. The new antibody against αSKA (10D2) is IgG2a, while anti-αCAA (22D3) is IgG1, which allows researchers to perform double staining in immunohistochemistry to distinguish these closely related actin isoforms. The validation in immunohistochemistry using rat tissues clearly demonstrates specific labeling of different subsets of cells by the isoform-specific antibodies. These antibodies should be outstanding resources to characterize actin isoform expression and subcellular localization in muscle development, regeneration, and diseases, as well as to investigate functions of actin isoforms. I have a few suggestions for a revision mostly for clarification purposes.

1. In abstract and introduction, “higher vertebrates” should be more clearly defined. Classification of six actin isoforms in 3 subgroups applies to mammals and birds. It should be useful for researchers who use non-mammalian or non-avian species to state whether this classification applies to other vertebrates. A recent analysis by Gunning et al. indicates that zebrafish has 10 muscle actins, suggesting some gene duplications and isoform divergence in fish.

2. Page 3, left column, 3rd paragraph, “sarcomers” should be “sarcomeres”.

3. In Materials and Methods “Antibody production and details”, this section should also include description of how the monoclonal antibodies were prepared after the clonal selection has been completed, which should include whether the antibodies were finally prepared in culture media with or without serum or in ascites, and whether protein concentrations were determined.

4. Also In Materials and Methods “Antibody production and details”, the selection process includes screening using Western blotting using extracts from several different tissues. To improve transparency of the validation process, representative images of the Western blots preferably showing a wide molecular weight range should be included to demonstrate specificity.

References

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Actin, alpha 2, smooth muscle, aorta
Danio rerio (Zebrafish) (Brachydanio rerio)
Q6DHS1-1
Ac-DDEESTALVC

Actin, alpha cardiac muscle 1 [Danio rerio]
Q6IQR3-1
Ac-DDDETTALVC

Actin, alpha 1, skeletal muscle
Danio rerio (Zebrafish) (Brachydanio rerio)
Q9I8V1-1
Ac-DDEETTALVC

According to the available sequence (although not reviewed), the N-terminus sequence of alpha 1, skeletal muscle in Zebrafish is identical to the alpha cardiac actin in mammals and birds!!! Furthermore, the N-terminus of alpha 2, smooth muscle, aorta and of alpha cardiac muscle are different compared to the α-SMA and α-CAA human and bird sequence.

2. sarcomers changed for sarcomeres.

3. Additional informations have been included in the "Material and Methods" section.

Yes the final antibody is obtained and used in "hybridoma supernatant" in the culture media with FCS for two reasons:
 a) Ascites production is not allowed in Switzerland for years.
 b) Hybridoma supernatants production is anyway privileged, as ascites are very often contaminated with unrelated antibodies with production time.
 c) Protein concentration was not determined precisely (in general, between 0.1-10 μg/ml). However, the dilution to be used is indicated in the report.

4. We provide a new figure (Supplemental figure 1), with raw data of Western blots on different tissue extracts, showing the specificity of the antibodies.

**Competing Interests:** No competing interests were disclosed.

Reviewer Report 11 April 2016
https://doi.org/10.5256/f1000research.8771.r13310

© 2016 Skalli O. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Omar Skalli  
Department of Biological Sciences, Integrated Microscopy Center(IMC), University of Memphis, Memphis, TN, USA

The paper by Chaponnier and Gabbiani reports the production of two monoclonal antibodies, one specific for skeletal actin and the other for cardiac actin. Being able to obtain these antibodies is a momentous accomplishment given that these two actin isoforms differ from each other by only a few amino acids. The authors rigorously demonstrate the specificity of each antibodies for their respective isoform by Western blotting and competitive assay with the immunogen. Because the antibodies are from different subtypes, they can be used by double immunofluorescence to investigate the regulation of skeletal and cardiac actin in different conditions. The authors provide stunningly beautiful immunofluorescence images that demonstrate the utility of their antibodies to pinpoint different cellular populations during skeletal muscle repair. It is to be expected that these antibodies will be extremely useful to studies questions related to cardiac and skeletal muscle physiology and pathology.

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 18 May 2016  
Christine Chaponnier, University of Geneva, Geneva, Switzerland

Your nice review and perfect understanding concerning the objectives of this report are highly appreciated.

**Competing Interests:** No competing interests were disclosed.

Reviewer Report 08 April 2016  
https://doi.org/10.5256/f1000research.8771.r13281

© 2016 Hashimoto N. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Naohiro Hashimoto  
Department of Regenerative Medicine, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, Ōbu, Japan

Higher vertebrates express six different highly conserved actin isoforms. The authors determined the precise localization of alpha-skeletal actin (aSKA) and alpha-cardiac actin (aCAA) in normal and regenerating rat skeletal muscles. The distinct distribution of the two alpha actin isoforms seems very interesting. However, the authors should describe the results of their immunofluorescent analysis on skeletal muscle more precisely and carefully.

1. The authors often used terms “renewing muscle (fibers)” and “regenerating fibers”. However, there is no definition of them. The authors should show the presence of centrally located nuclei in those
myofibers because those are found in newly formed myofibers.

2. The authors identified myofibroblasts in regenerating skeletal muscles as the alpha-SMA (aSMA) positive mononuclear cells. However, myoblasts also express aSMA. Thus, the authors should determine the absence of myogenic lineage markers such as MyoD in those cells.

3. Intracellular localization of alpha actin isoforms should be shown in pictures with higher magnification in addition to the present Figure 2 and 3. Those data will provide important information suggesting different function of those actin isoforms.

4. The term “self-renewal” is used incorrectly. For examples, “self-renewal in muscle cells” and “during muscle self-renewal” are difficult to understand. I wonder whether “muscle cells” mean muscle satellite cells, myoblasts (muscle progenitor cells), or myofibers. “Muscle self-renewal” means muscle regeneration?

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

---

**Author Response 18 May 2016**

**Christine Chaponnier,** University of Geneva, Geneva, Switzerland

Your careful review and suggestions for improving the report are highly appreciated. Please find below our answers to your questions.

1. a) We have modified the text according to the suggestion using in general the term regeneration and not renewal.
   b) Enlargement of Figure 2Af and 3Ai showing αCAA positive myofibers with centrally located nuclei during muscle regeneration. (See supplemental Figure 2)

2. a) The injury model used in this study is in general not accompanied by fibrotic events during the healing process. Only, in rare exceptions, as mentioned in the text, myofibroblasts were detected. We have a long experience in the “myofibroblast history”, and according to the α-SMA positivity and the cell shape, we believe that this area is composed of myofibroblasts.

   b) We agree that the absence of MyoD would validate our assumption. However, the purpose of this report is the validation of the actin isoforms antibodies and not a extensive study on muscle regeneration. We hope that muscle experts will take advantage of these tools for more advanced studies.

3. As indicated above, the purpose of this report is the validation of the actin isoforms antibodies. The intracellular localization of α-SMA, sometimes in striations, will not give clear information concerning its function in muscle regeneration.

4. a) See answer to point 1
b) Future studies by experts, hopefully using the panel of antibodies against actin isoforms, will provide more information for the participation of satellite cells during the process of muscle regeneration.

**Competing Interests:** No competing interests were disclosed.

---

## Comments on this article

*Version 1*

Reader Comment 05 Apr 2016

**Anita Bandrowski,** University of California, San Diego, USA

Dear Drs. Chaponnier and Gabbiani,

Your table 1 is very useful in bringing together lots of information about antibodies that are being resold by many vendors. This is critical information that we will code into the antibodyregistry.org to help future authors avoid mistakes in cross-validation.

However, it seems that you have not registered your new antibodies with the antibodyregistry.org. This step is recommended by the instructions to authors at F1000 and also NIH grantees starting in May 2016, please see: [http://f1000.com/resources/F1000Research-Antibody-Validation-Article-Template.docx](http://f1000.com/resources/F1000Research-Antibody-Validation-Article-Template.docx)

For the Dako antibody, the reference is most likely Dako Cat# M0725, RRID:AB_10013485, but please search the antibodyregistry.org to verify.

**Competing Interests:** I run the antibodyregistry.org and the resource identification initiative at Force11.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage